항결핵 치료제 시장 : 세계 산업 규모, 점유율, 동향, 기회, 예측 - 질환 유형별, 진단·치료별(진단, 치료, 기타), 최종사용자별, 지역별, 경쟁별(2020-2030년)
Anti-Tuberculosis Therapeutics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Disease Type, By Diagnosis and Treatment (Diagnosis, Treatment, others), By End User, By Region & Competition, 2020-2030F
상품코드:1691770
리서치사:TechSci Research
발행일:2025년 03월
페이지 정보:영문 182 Pages
라이선스 & 가격 (부가세 별도)
ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
한글목차
세계의 항결핵 치료제 시장은 2024년에 13억 2,050만 달러에 달하며, 2030년까지 CAGR은 5.90%로, 예측 기간 중 인상적인 성장을 달성할 것으로 예측됩니다. 항결핵 치료제는 주로 결핵균에 의해 발생하는 세균성 감염 질환인 결핵을 관리하고 치료하는 데 사용되는 약물 및 치료 전략을 말합니다. 결핵은 주로 폐에 감염되는 전염병이지만 신체의 다른 장기나 시스템에도 영향을 미칠 수 있습니다. 결핵의 확산을 억제하고 합병증을 예방하기 위해서는 효과적인 항결핵 치료제가 필수적입니다. 약제 감수성 결핵에 대한 표준 치료 요법은 일반적으로 1차 선택 약물을 조합하여 6-9개월 동안 매일 복용하는 것입니다. 이 치료 기간은 중증도, 환자의 치료 반응 등의 요인에 따라 달라질 수 있습니다. 약제 내성 결핵의 치료는 더 복잡하며, 때로는 2차 선택 약물을 사용하기도 합니다. 치료 기간은 18개월에서 24개월 또는 그 이상 지속될 수 있으며, 사용되는 특정 약제는 결핵균의 내성 패턴에 따라 달라질 수 있습니다. 항결핵 치료를 받는 환자는 치료 반응을 평가하고 부작용을 발견하기 위해 정기적으로 모니터링합니다. 모니터링에는 임상 평가, 임상 검사, 방사선 검사 등이 포함됩니다.
시장 개요
예측 기간
2026-2030년
시장 규모 : 2024년
13억 2,050만 달러
시장 규모 : 2030년
18억 4,748만 달러
CAGR: 2025-2030년
5.90%
급성장 부문
활동성 결핵
최대 시장
북미
주요 시장 성장 촉진요인
약제 내성 결핵 균주의 출현
주요 시장 과제
편견과 사회적 결정요인
주요 시장 동향
치료 요법의 단순화
목차
제1장 제품 개요
제2장 조사 방법
제3장 개요
제4장 고객의 소리
제5장 세계의 항결핵 치료제 시장 전망
시장 규모·예측
금액별
시장 점유율·예측
질환 유형별(활동성 결핵, 잠복 결핵, 기타)
진단·치료별(진단(혈액검사, 영상 검사, 객담 검사, 기타), 치료(제1 선택약, 제2 선택약, 기타), 기타)
최종사용자별(병원, 전문 클리닉, 홈케어 등)
지역별
기업별(2024년)
시장 맵
제6장 아시아태평양의 항결핵 치료제 시장 전망
시장 규모·예측
시장 점유율·예측
아시아태평양 : 국가별 분석
인도
호주
일본
한국
제7장 유럽의 항결핵 치료제 시장 전망
시장 규모·예측
시장 점유율·예측
유럽 : 국가별 분석
독일
스페인
이탈리아
영국
제8장 북미의 항결핵 치료제 시장 전망
시장 규모·예측
시장 점유율·예측
북미 : 국가별 분석
멕시코
캐나다
제9장 남미의 항결핵 치료제 시장 전망
시장 규모·예측
시장 점유율·예측
남미 : 국가별 분석
아르헨티나
콜롬비아
제10장 중동 및 아프리카의 항결핵 치료제 시장 전망
시장 규모·예측
시장 점유율·예측
중동 및 아프리카 : 국가별 분석
사우디아라비아
아랍에미리트
제11장 시장 역학
촉진요인
과제
제12장 시장 동향과 발전
최근 동향
제품 출시
합병과 인수
제13장 세계의 항결핵 치료제 시장 : SWOT 분석
제14장 Porter's Five Forces 분석
업계내 경쟁
신규 참여의 가능성
공급업체의 힘
고객의 힘
대체품의 위협
제15장 PESTEL 분석
제16장 경쟁 구도
AstraZeneca Plc
Johnson & Johnson Private Limited
Eli Lilly and Company
F. Hoffmann-La Roche Ltd.
Mylan N.V.
Teva Pharmaceutical Industries Ltd.
Sanofi SA
Novartis AG
Sun Pharmaceutical Industries Ltd.
Merck & Co., Inc.
제17장 전략적 제안
제18장 조사회사 소개·면책사항
KSA
영문 목차
영문목차
Global Anti-Tuberculosis Therapeutics Market was valued at USD 1320.50 million in 2024 and is anticipated to witness an impressive growth in the forecast period with a CAGR of 5.90% through 2030. Anti-tuberculosis (TB) therapeutics refer to the medications and treatment strategies used to manage and cure tuberculosis, a bacterial infection primarily caused by Mycobacterium tuberculosis. TB is a contagious disease that primarily affects the lungs but can also affect other organs and systems in the body. Effective anti-TB therapeutics are essential for controlling the spread of TB and preventing its complications. Standard treatment regimens for drug-susceptible TB typically involve a combination of first-line drugs taken daily for six to nine months. This duration may vary based on factors like the severity of the disease and the patient's response to treatment. Treatment for drug-resistant TB is more complex and may involve second-line drugs. Regimens can last for 18 to 24 months or longer, and the specific drugs used depend on the resistance pattern of the TB bacteria. Patients receiving anti-TB treatment are regularly monitored to assess their response to treatment and to detect any adverse effects. Monitoring includes clinical evaluations, laboratory tests, and radiological examinations.
Market Overview
Forecast Period
2026-2030
Market Size 2024
USD 1320.50 Million
Market Size 2030
USD 1847.48 Million
CAGR 2025-2030
5.90%
Fastest Growing Segment
Active TB
Largest Market
North America
Key Market Drivers
Emergence of Drug-Resistant TB Strains
Drug-resistant TB occurs when the bacterium that causes TB, Mycobacterium tuberculosis, becomes resistant to one or more of the drugs commonly used to treat the disease. Multidrug-Resistant TB (MDR-TB) is defined as resistance to both isoniazid and rifampin, which are the two most potent first-line anti-TB drugs. MDR-TB is more challenging to treat than drug-susceptible TB because it requires a longer duration of treatment with second-line drugs, which are less effective and often have more side effects. Extensively Drug-Resistant TB (XDR-TB) is a more severe form of drug resistance and is defined as resistance to isoniazid and rifampin (MDR-TB) plus resistance to any fluoroquinolone and at least one of three injectable second-line drugs (amikacin, kanamycin, or capreomycin). XDR-TB is even more challenging to treat and often requires highly toxic medications with limited efficacy.
One of the primary factors driving drug resistance is the incomplete or inadequate treatment of TB. When patients do not complete the full course of their prescribed TB medications or when the drugs are not administered correctly, it creates conditions that allow the TB bacteria to develop resistance to the drugs. The inappropriate use of antibiotics, including the use of TB drugs for non-TB infections or the use of low-quality or substandard medications, can contribute to drug resistance. Patients may fail to adhere to their TB treatment regimens for various reasons, such as experiencing side effects, stigma associated with TB, or challenges with accessing healthcare services.
Non-adherence can result in treatment failure and drug resistance. Drug-resistant TB strains can be transmitted from person to person. Close contact with an individual infected with a drug-resistant strain can lead to new cases of drug-resistant TB. Poor infection control measures in healthcare settings can facilitate the spread of drug-resistant TB strains, particularly in hospitals and clinics. In some regions, there may be limited access to second-line anti-TB drugs or diagnostic tools to detect drug resistance. This can delay the identification and appropriate treatment of drug-resistant cases. Individuals with compromised immune systems, such as those living with HIV, are at higher risk of developing drug-resistant TB due to their reduced ability to fight off the infection. This factor will help in the development of the Global Anti-Tuberculosis Therapeutics Market.
Key Market Challenges
Stigma and Social Determinants
TB has historically carried a social stigma due to its contagious nature. People with TB may face discrimination and social isolation, which can discourage them from seeking diagnosis and treatment. Individuals diagnosed with TB may internalize societal stigma, leading to feelings of shame and guilt. This self-stigma can negatively affect mental health and willingness to adhere to treatment. Stigma can lead to delays in seeking diagnosis and treatment. Individuals may avoid healthcare facilities out of fear of being stigmatized, leading to delayed diagnosis and worsening of their condition. Stigmatized individuals may be less likely to adhere to their TB treatment regimens, which can lead to treatment failure and the development of drug-resistant TB strains.
Social determinants such as poverty, homelessness, and limited access to healthcare are often linked to a higher risk of TB. Vulnerable populations face increased challenges in accessing diagnosis and treatment, exacerbating the impact of stigma. TB-HIV co-infected individuals often face compounded stigma and discrimination. Managing both diseases require specialized care and support. Reducing TB-related stigma requires education and awareness campaigns that address misconceptions and promote empathy and understanding. These initiatives are essential but require resources and sustained efforts.
Key Market Trends
Treatment Regimen Simplification
Traditional TB treatment regimens often involve multiple pills taken daily for several months. Simplified regimens aim to reduce the number of pills, making it easier for patients to adhere to their treatment plans. Fixed-Dose Combinations (FDCs) combine multiple anti-TB drugs into a single tablet, reducing the complexity of treatment. This approach simplifies dosing schedules and enhances patient adherence. Efforts are underway to develop shorter-duration treatment regimens for TB. For example, some clinical trials have explored the feasibility of shorter treatment courses, such as the 4-month regimen for rifampin-sensitive TB. Simplified regimens may involve fewer clinic visits for drug administration or monitoring. This is particularly important for patients who face challenges in accessing healthcare facilities.
Integrating TB treatment with other healthcare services, such as HIV care, maternal and child health, and non-communicable disease management, can simplify care for patients with multiple health needs. Developing pediatric-friendly formulations of anti-TB drugs, including child-appropriate FDCs and liquid formulations, simplifies treatment for children with TB. Mobile health (mHealth) technologies and digital tools can provide treatment reminders, track medication adherence, and support patients in adhering to their treatment regimens. Community health workers and TB treatment supporters can play a crucial role in simplifying treatment by delivering medications to patients in their communities and providing support. Improved diagnostics, such as molecular tests that rapidly detect TB and drug resistance, contribute to more precise treatment decisions and regimens.
Key Market Players
AstraZeneca Plc.
Johnson & Johnson Private Limited
Eli Lilly and Company
F. Hoffmann-La Roche Ltd.
Mylan N.V.
Teva Pharmaceutical Industries Ltd.
Sanofi SA
Novartis AG
Sun Pharmaceutical Industries Ltd.
Merck & Co., Inc.
Report Scope:
In this report, the Global Anti-Tuberculosis Therapeutics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:
Anti-Tuberculosis Therapeutics Market, By Disease Type:
Active TB
Latent TB
Others
Anti-Tuberculosis Therapeutics Market, By Diagnostic and Treatment:
Diagnosis
Blood Tests
Imaging Tests
Sputum Tests
Others
Treatment
First Line of Drug
O Isoniazid
O Ethambutol
O Rifampin
O Others
Second Line of Drugs
O Thiacetazone
O Paraaminosalicyclic Acid (PAS)
O Others
Others
Others
Anti-Tuberculosis Therapeutics Market, By End-User:
Hospitals
Specialty Clinics
Homecare
Others
Anti-Tuberculosis Therapeutics Market, By region:
North America
United States
Canada
Mexico
Asia-Pacific
China
India
South Korea
Australia
Japan
Europe
Germany
France
United Kingdom
Spain
Italy
South America
Brazil
Argentina
Colombia
Middle East & Africa
South Africa
Saudi Arabia
UAE
Competitive Landscape
Company Profiles: Detailed analysis of the major companies present in the Global Anti-Tuberculosis Therapeutics Market.
Available Customizations:
Global Anti-Tuberculosis Therapeutics Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:
Company Information
Detailed analysis and profiling of additional market players (up to five).
Table of Contents
1. Product Overview
1.1. Market Definition
1.2. Scope of the Market
1.2.1. Markets Covered
1.2.2. Years Considered for Study
1.2.3. Key Market Segmentations
2. Research Methodology
2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations
3. Executive Summary
3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends
4. Voice of Customer
5. Global Anti-Tuberculosis Therapeutics Market Outlook
5.1. Market Size & Forecast
5.1.1. By Value
5.2. Market Share & Forecast
5.2.1. By Disease Type (Active TB, Latent TB, Others)
5.2.2. By Diagnosis and Treatment (Diagnosis (Blood Tests, Imaging Tests, Sputum Tests, Others), Treatment (First Line of Drugs, Second Line of Drugs, others), others)
5.2.3. By End User (Hospitals, Specialty Clinics, Homecare, others)
5.2.4. By Region
5.2.5. By Company (2024)
5.3. Market Map
6. Asia Pacific Anti-Tuberculosis Therapeutics Market Outlook
6.1. Market Size & Forecast
6.1.1. By Value
6.2. Market Share & Forecast
6.2.1. By Disease Type
6.2.2. By Diagnosis and Treatment
6.2.3. By End User
6.2.4. By Country
6.3. Asia Pacific: Country Analysis
6.3.1. China Anti-Tuberculosis Therapeutics Market Outlook
6.3.1.1. Market Size & Forecast
6.3.1.1.1. By Value
6.3.1.2. Market Share & Forecast
6.3.1.2.1. By Disease Type
6.3.1.2.2. By Diagnosis and Treatment
6.3.1.2.3. By End User
6.3.2. India Anti-Tuberculosis Therapeutics Market Outlook
6.3.2.1. Market Size & Forecast
6.3.2.1.1. By Value
6.3.2.2. Market Share & Forecast
6.3.2.2.1. By Disease Type
6.3.2.2.2. By Diagnosis and Treatment
6.3.2.2.3. By End User
6.3.3. Australia Anti-Tuberculosis Therapeutics Market Outlook
6.3.3.1. Market Size & Forecast
6.3.3.1.1. By Value
6.3.3.2. Market Share & Forecast
6.3.3.2.1. By Disease Type
6.3.3.2.2. By Diagnosis and Treatment
6.3.3.2.3. By End User
6.3.4. Japan Anti-Tuberculosis Therapeutics Market Outlook
6.3.4.1. Market Size & Forecast
6.3.4.1.1. By Value
6.3.4.2. Market Share & Forecast
6.3.4.2.1. By Disease Type
6.3.4.2.2. By Diagnosis and Treatment
6.3.4.2.3. By End User
6.3.5. South Korea Anti-Tuberculosis Therapeutics Market Outlook
6.3.5.1. Market Size & Forecast
6.3.5.1.1. By Value
6.3.5.2. Market Share & Forecast
6.3.5.2.1. By Disease Type
6.3.5.2.2. By Diagnosis and Treatment
6.3.5.2.3. By End User
7. Europe Anti-Tuberculosis Therapeutics Market Outlook
7.1. Market Size & Forecast
7.1.1. By Value
7.2. Market Share & Forecast
7.2.1. By Disease Type
7.2.2. By Diagnosis and Treatment
7.2.3. By End User
7.2.4. By Country
7.3. Europe: Country Analysis
7.3.1. France Anti-Tuberculosis Therapeutics Market Outlook
7.3.1.1. Market Size & Forecast
7.3.1.1.1. By Value
7.3.1.2. Market Share & Forecast
7.3.1.2.1. By Disease Type
7.3.1.2.2. By Diagnosis and Treatment
7.3.1.2.3. By End User
7.3.2. Germany Anti-Tuberculosis Therapeutics Market Outlook
7.3.2.1. Market Size & Forecast
7.3.2.1.1. By Value
7.3.2.2. Market Share & Forecast
7.3.2.2.1. By Disease Type
7.3.2.2.2. By Diagnosis and Treatment
7.3.2.2.3. By End User
7.3.3. Spain Anti-Tuberculosis Therapeutics Market Outlook
7.3.3.1. Market Size & Forecast
7.3.3.1.1. By Value
7.3.3.2. Market Share & Forecast
7.3.3.2.1. By Disease Type
7.3.3.2.2. By Diagnosis and Treatment
7.3.3.2.3. By End User
7.3.4. Italy Anti-Tuberculosis Therapeutics Market Outlook
7.3.4.1. Market Size & Forecast
7.3.4.1.1. By Value
7.3.4.2. Market Share & Forecast
7.3.4.2.1. By Disease Type
7.3.4.2.2. By Diagnosis and Treatment
7.3.4.2.3. By End User
7.3.5. United Kingdom Anti-Tuberculosis Therapeutics Market Outlook
7.3.5.1. Market Size & Forecast
7.3.5.1.1. By Value
7.3.5.2. Market Share & Forecast
7.3.5.2.1. By Disease Type
7.3.5.2.2. By Diagnosis and Treatment
7.3.5.2.3. By End User
8. North America Anti-Tuberculosis Therapeutics Market Outlook
8.1. Market Size & Forecast
8.1.1. By Value
8.2. Market Share & Forecast
8.2.1. By Disease Type
8.2.2. By Diagnosis and Treatment
8.2.3. By End User
8.2.4. By Country
8.3. North America: Country Analysis
8.3.1. United States Anti-Tuberculosis Therapeutics Market Outlook
8.3.1.1. Market Size & Forecast
8.3.1.1.1. By Value
8.3.1.2. Market Share & Forecast
8.3.1.2.1. By Disease Type
8.3.1.2.2. By Diagnosis and Treatment
8.3.1.2.3. By End User
8.3.2. Mexico Anti-Tuberculosis Therapeutics Market Outlook
8.3.2.1. Market Size & Forecast
8.3.2.1.1. By Value
8.3.2.2. Market Share & Forecast
8.3.2.2.1. By Disease Type
8.3.2.2.2. By Diagnosis and Treatment
8.3.2.2.3. By End User
8.3.3. Canada Anti-Tuberculosis Therapeutics Market Outlook
8.3.3.1. Market Size & Forecast
8.3.3.1.1. By Value
8.3.3.2. Market Share & Forecast
8.3.3.2.1. By Disease Type
8.3.3.2.2. By Diagnosis and Treatment
8.3.3.2.3. By End User
9. South America Anti-Tuberculosis Therapeutics Market Outlook
9.1. Market Size & Forecast
9.1.1. By Value
9.2. Market Share & Forecast
9.2.1. By Disease Type
9.2.2. By Diagnosis and Treatment
9.2.3. By End User
9.2.4. By Country
9.3. South America: Country Analysis
9.3.1. Brazil Anti-Tuberculosis Therapeutics Market Outlook
9.3.1.1. Market Size & Forecast
9.3.1.1.1. By Value
9.3.1.2. Market Share & Forecast
9.3.1.2.1. By Disease Type
9.3.1.2.2. By Diagnosis and Treatment
9.3.1.2.3. By End User
9.3.2. Argentina Anti-Tuberculosis Therapeutics Market Outlook
9.3.2.1. Market Size & Forecast
9.3.2.1.1. By Value
9.3.2.2. Market Share & Forecast
9.3.2.2.1. By Disease Type
9.3.2.2.2. By Diagnosis and Treatment
9.3.2.2.3. By End User
9.3.3. Colombia Anti-Tuberculosis Therapeutics Market Outlook
9.3.3.1. Market Size & Forecast
9.3.3.1.1. By Value
9.3.3.2. Market Share & Forecast
9.3.3.2.1. By Disease Type
9.3.3.2.2. By Diagnosis and Treatment
9.3.3.2.3. By End User
10. Middle East and Africa Anti-Tuberculosis Therapeutics Market Outlook
10.1. Market Size & Forecast
10.1.1. By Value
10.2. Market Share & Forecast
10.2.1. By Disease Type
10.2.2. By Diagnosis and Treatment
10.2.3. By End User
10.2.4. By Country
10.3. MEA: Country Analysis
10.3.1. South Africa Anti-Tuberculosis Therapeutics Market Outlook
10.3.1.1. Market Size & Forecast
10.3.1.1.1. By Value
10.3.1.2. Market Share & Forecast
10.3.1.2.1. By Disease Type
10.3.1.2.2. By Diagnosis and Treatment
10.3.1.2.3. By End User
10.3.2. Saudi Arabia Anti-Tuberculosis Therapeutics Market Outlook
10.3.2.1. Market Size & Forecast
10.3.2.1.1. By Value
10.3.2.2. Market Share & Forecast
10.3.2.2.1. By Disease Type
10.3.2.2.2. By Diagnosis and Treatment
10.3.2.2.3. By End User
10.3.3. UAE Anti-Tuberculosis Therapeutics Market Outlook
10.3.3.1. Market Size & Forecast
10.3.3.1.1. By Value
10.3.3.2. Market Share & Forecast
10.3.3.2.1. By Disease Type
10.3.3.2.2. By Diagnosis and Treatment
10.3.3.2.3. By End User
11. Market Dynamics
11.1. Drivers
11.2. Challenges
12. Market Trends & Developments
12.1. Recent Developments
12.2. Product Launches
12.3. Mergers & Acquisitions
13. Global Anti-Tuberculosis Therapeutics Market: SWOT Analysis
